Aubrai ($AUBRAI)

Recent developments:

0% of the initial token allocation is held by the creator.

Creator token stats last updated: Aug 22, 2025 16:38

The following is generated by an LLM:

Summary

longevity research AI with zero creator allocation

Analysis

Aubrai ($AUBRAI) aims to use blockchain technology to accelerate longevity research by creating an AI agent that aggregates scientific papers, critiques study designs, and provides updates on the ambitious RMR2 mouse study. The project has significant scientific ambitions and reputable associations, including Dr. Aubrey de Grey. However, the tokenomics reveal critical flaws: the creator holds 0% of the token supply, which fundamentally misaligns incentives and violates core investment principles. Without skin in the game, the creator lacks economic commitment to the project's success. The token utility remains unclear, providing no obvious reason for token demand beyond speculation. The anonymous team (only known through minimal wallet activity) and absence of legal entity information further amplify risks. While the science could be meaningful, these structural flaws make the token uninvestable.

Rating: 0

Generated with LLM: deepseek/deepseek-r1

LLM responses last updated: Aug 22, 2025 16:39

Original investment data:

# Aubrai ($AUBRAI) URL on launchpad: https://app.virtuals.io/prototypes/0x1Fcf063f4d15e2B58563bFD7AF86568062CbCd6B Launched at: Fri, 22 Aug 2025 16:37:38 GMT Launched through the launchpad: Virtuals Protocol Launch status: UNDERGRAD ## Token details and tokenomics Token address: 0x1Fcf063f4d15e2B58563bFD7AF86568062CbCd6B Top holders: https://basescan.org/token/0x1Fcf063f4d15e2B58563bFD7AF86568062CbCd6B#balances Liquidity contract: https://basescan.org/address/0x74b5b589cd28E314C9305e7315EF80D384DE4a5e#asset-tokens Token symbol: $AUBRAI Token supply: 1 billion Creator initial number of tokens: Creator initial number of tokens: 0 (0% of token supply) ## Creator info Creator address: 0x02908957173ae116d59E84d3fAdd7953183D513A Creator on basescan.org: https://basescan.org/address/0x02908957173ae116d59E84d3fAdd7953183D513A#asset-tokens Creator on virtuals.io: https://app.virtuals.io/profile/0x02908957173ae116d59E84d3fAdd7953183D513A Creator on zerion.io: https://app.zerion.io/0x02908957173ae116d59E84d3fAdd7953183D513A/overview Creator on debank.com: https://debank.com/profile/0x02908957173ae116d59E84d3fAdd7953183D513A ## Description at launch AUBRAI is an on-chain AI agent that accelerates longevity research. Built with the expertise of Dr. Aubrey de Grey and myself - @Leooweb3 as the Co-developed and communications representative AUBRAI aggregates papers, critiques study designs, and shares live updates on RMR2 ## Overview Aubrai is the world’s first decentralized scientific agent with knowledge stemming from thousands of private lab notes, internal chats and unpublished insights from the lab of Dr. Aubrey de Grey and the collective intelligence of the global longevity community. Co-developed/CMO by [@Leooweb3](https://x.com/Leooweb3) , the first Agent is designed to fight the greatest killer of all time: Aging. As an onchain AI co-scientitst, Aubrai can generate and validate hypotheses, design wet-lab experiments and encrypt data when asked, enriching research outputs while protecting trade secrets. At the heart of Aubrai's mission lies the Robust Mouse Rejuvenation (RMR2) project – Aubrey's ambitious study to double the remaining lifespan of middle‑aged mice. If successful, it could be aging's "AlphaFold moment": a proof that multi‑target rejuvenation works and is worth scaling. **Strategic Evolution from RMR1:** Key improvements following the results of the first RMR study include: * A larger number (8) of treatments will be included, targeting additional aging mechanisms. * Treatments that were not available (or verified) when RMR1 commenced are being included. * Some damage-repair interventions will be given repeatedly, rather than (as in RMR1) just once. * The use of smart cage technology will enable enhanced monitoring. * All animals (apart from in the true control groups) will receive rapamycin as a baseline treatment, as well as running wheels. **Age at study initiation:** As in RMR1, interventions will begin in mid-late life, between 18-20 months of age, in order to assess the repair/rejuvenation capacity of interventions. The study will run through the remaining lifespan of all mice with the exception of animals selected for cross-sectional analysis at timepoints, as in RMR1. **Mouse Strain:** RMR2 is expected to utilize CL57BL/6J mice, although we may switch to HET3, which are now available pre-aged through Jackson Laboratories. We are evaluating the benefits and drawbacks of both these strains and will update when a decision has been reached. **Treatment Groups:** RMR2 is planned to include 20 different combinations of treatments, whereas there were only 10 in RMR1. This includes groups of mice receiving just one intervention so as to validate that we are successfully recapitulating effects reported in prior work. We continue to reason that little additional information would result from also including the various possible combinations of from two to six of the interventions. Seven out of eight, on the other hand, gives key information, especially on the existence of any antagonistic interactions. Other groups will be receiving all eight interventions. **Scale of study:** We aim to conduct RMR2 on a similar basis as RMR1: two groups (one male and one female) for each of the 20 combinations being tested, with 50 animals in each group. This totals 1000 male and 1000 female mice. In the event of funding limitations, we may alternatively opt to start by conducting RMR2 in only one sex, which cuts the study size in half, while maintaining statistical power for individual treatment groups. While this will enable us to initiate RMR2 more expediently, using a single sex remains suboptimal due to significant known sexual dimorphism in mouse lifespan studies - including RMR1. **Baseline treatments:** Combination therapies are only valuable if their benefit exceeds that of the best known alternative. To date, the most effective rejuvenation treatments are rapamycin, caloric restriction, and exercise. We carefully considered these in the context of RMR1, opting to include rapamycin as one of the four interventions for comparison. For RMR2, we are giving rapamycin to ALL the animals in all treatment groups. This will allow us to gauge the efficacy of other rejuvenation interventions when the overall damage burden is already slightly lowered. Similarly, we have determined that animals in the RMR2 study will have access to a running wheel in their cages, permitting voluntary exercise. While the animals in RMR1 are provided some enrichment such as nesting material, wheels are not standard in conventional rodent housing. Physical activity is known to be a strong determinant of healthspan in both animals and humans, and we believe that no intervention can be maximally effective in obese, inactive mice. We do not consider this addition to be an “intervention” in itself, but rather a basic requirement in order to delay aging pathologies. **Data Collection:** We intend to collect laboratory and functional data longitudinally, as RMR1, in addition to hematological and tissue data cross-sectionally from culled animals and from those humanely euthanized during the course of the study. We are keen to establish collaborations with academics and industry researchers to take full advantage of the information potential arising from the study and the expertise of the research community. If you are interested in biospecimen or data from RMR2 for your field of study, please contact us at [science@levf.org](mailto:science@levf.org) to discuss further. ## Additional information extracted from relevant pages <fetched_info> """ https://x.com/Leooweb3 Skipped social media URL (https://x.com/Leooweb3) - requires authentication """ """ [Creator profile on Virtuals Protocol](https://api.virtuals.io/api/profile/0x02908957173ae116d59E84d3fAdd7953183D513A) { "data": { "id": 496449, "displayName": null, "bio": null, "avatar": null, "userSocials": [ { "id": 560540, "provider": "okx_wallet", "walletAddress": "0x02908957173ae116d59E84d3fAdd7953183D513A", "metadata": null } ], "socials": null } } """ </fetched_info> <full_details> { "id": 36888, "uid": "8e623eec-9d72-4a8f-9bde-11a2409fa028", "createdAt": "2025-08-22T16:37:38.634Z", "walletAddress": "0x02908957173ae116d59E84d3fAdd7953183D513A", "name": "Aubrai", "description": "AUBRAI is an on-chain AI agent that accelerates longevity research. Built with the expertise of Dr. Aubrey de Grey and myself - @Leooweb3 as the Co-developed and communications representative\n\nAUBRAI aggregates papers, critiques study designs, and shares live updates on RMR2", "sentientWalletAddress": null, "category": "IP MIRROR", "role": "PRODUCTIVITY", "daoAddress": null, "tokenAddress": null, "virtualId": null, "status": "UNDERGRAD", "symbol": "AUBRAI", "lpAddress": null, "veTokenAddress": null, "totalValueLocked": null, "virtualTokenValue": null, "holderCount": null, "mcapInVirtual": null, "preToken": "0x1Fcf063f4d15e2B58563bFD7AF86568062CbCd6B", "preTokenPair": "0x74b5b589cd28E314C9305e7315EF80D384DE4a5e", "aidesc": null, "firstMessage": null, "socials": null, "tbaAddress": null, "chain": "BASE", "mainVirtualId": null, "top10HolderPercentage": null, "level": 1, "valueFx": 0, "priceChangePercent24h": 0, "volume24h": 0, "mindshare": null, "migrateTokenAddress": null, "lpCreatedAt": null, "stakingAddress": null, "agentStakingContract": null, "merkleDistributor": null, "isVerified": false, "airdropMerkleDistributor": null, "isDevCommitted": false, "tokenUtility": "", "showFounderVideo": false, "roadmap": "Initializing 90%...", "additionalDetails": "", "overview": "Aubrai is the world’s first decentralized scientific agent with knowledge stemming from thousands of private lab notes, internal chats and unpublished insights from the lab of Dr. Aubrey de Grey and the collective intelligence of the global longevity community.\n\nCo-developed/CMO by [@Leooweb3](https://x.com/Leooweb3) , the first Agent is designed to fight the greatest killer of all time: Aging. As an onchain AI co-scientitst, Aubrai can generate and validate hypotheses, design wet-lab experiments and encrypt data when asked, enriching research outputs while protecting trade secrets. At the heart of Aubrai's mission lies the Robust Mouse Rejuvenation (RMR2) project – Aubrey's ambitious study to double the remaining lifespan of middle‑aged mice. If successful, it could be aging's \"AlphaFold moment\": a proof that multi‑target rejuvenation works and is worth scaling.\n\n**Strategic Evolution from RMR1:** Key improvements following the results of the first RMR study include:\n\n* A larger number (8) of treatments will be included, targeting additional aging mechanisms.\n* Treatments that were not available (or verified) when RMR1 commenced are being included.\n* Some damage-repair interventions will be given repeatedly, rather than (as in RMR1) just once.\n* The use of smart cage technology will enable enhanced monitoring.\n* All animals (apart from in the true control groups) will receive rapamycin as a baseline treatment, as well as running wheels.\n\n**Age at study initiation:** As in RMR1, interventions will begin in mid-late life, between 18-20 months of age, in order to assess the repair/rejuvenation capacity of interventions. The study will run through the remaining lifespan of all mice with the exception of animals selected for cross-sectional analysis at timepoints, as in RMR1.\n\n**Mouse Strain:** RMR2 is expected to utilize CL57BL/6J mice, although we may switch to HET3, which are now available pre-aged through Jackson Laboratories. We are evaluating the benefits and drawbacks of both these strains and will update when a decision has been reached.\n\n**Treatment Groups:** RMR2 is planned to include 20 different combinations of treatments, whereas there were only 10 in RMR1. This includes groups of mice receiving just one intervention so as to validate that we are successfully recapitulating effects reported in prior work. We continue to reason that little additional information would result from also including the various possible combinations of from two to six of the interventions. Seven out of eight, on the other hand, gives key information, especially on the existence of any antagonistic interactions. Other groups will be receiving all eight interventions.\n\n**Scale of study:** We aim to conduct RMR2 on a similar basis as RMR1: two groups (one male and one female) for each of the 20 combinations being tested, with 50 animals in each group. This totals 1000 male and 1000 female mice. In the event of funding limitations, we may alternatively opt to start by conducting RMR2 in only one sex, which cuts the study size in half, while maintaining statistical power for individual treatment groups. While this will enable us to initiate RMR2 more expediently, using a single sex remains suboptimal due to significant known sexual dimorphism in mouse lifespan studies - including RMR1.\n\n**Baseline treatments:** Combination therapies are only valuable if their benefit exceeds that of the best known alternative. To date, the most effective rejuvenation treatments are rapamycin, caloric restriction, and exercise. We carefully considered these in the context of RMR1, opting to include rapamycin as one of the four interventions for comparison. For RMR2, we are giving rapamycin to ALL the animals in all treatment groups. This will allow us to gauge the efficacy of other rejuvenation interventions when the overall damage burden is already slightly lowered.\n\nSimilarly, we have determined that animals in the RMR2 study will have access to a running wheel in their cages, permitting voluntary exercise. While the animals in RMR1 are provided some enrichment such as nesting material, wheels are not standard in conventional rodent housing. Physical activity is known to be a strong determinant of healthspan in both animals and humans, and we believe that no intervention can be maximally effective in obese, inactive mice. We do not consider this addition to be an “intervention” in itself, but rather a basic requirement in order to delay aging pathologies.\n\n**Data Collection:** We intend to collect laboratory and functional data longitudinally, as RMR1, in addition to hematological and tissue data cross-sectionally from culled animals and from those humanely euthanized during the course of the study.\n\nWe are keen to establish collaborations with academics and industry researchers to take full advantage of the information potential arising from the study and the expertise of the research community. If you are interested in biospecimen or data from RMR2 for your field of study, please contact us at [science@levf.org](mailto:science@levf.org) to discuss further.", "image": { "id": 50574, "name": "36888_346a77f7-7e94-4e61-a1a0-435a9338ced1.webp", "alternativeText": null, "caption": null, "width": 1200, "height": 1007, "formats": { "large": { "ext": ".webp", "url": "https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/large_36888_346a77f7_7e94_4e61_a1a0_435a9338ced1_3d9790c0f0.webp", "hash": "large_36888_346a77f7_7e94_4e61_a1a0_435a9338ced1_3d9790c0f0", "mime": "image/webp", "name": "large_36888_346a77f7-7e94-4e61-a1a0-435a9338ced1.webp", "path": null, "size": 39.41, "width": 1000, "height": 839 }, "small": { "ext": ".webp", "url": "https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/small_36888_346a77f7_7e94_4e61_a1a0_435a9338ced1_3d9790c0f0.webp", "hash": "small_36888_346a77f7_7e94_4e61_a1a0_435a9338ced1_3d9790c0f0", "mime": "image/webp", "name": "small_36888_346a77f7-7e94-4e61-a1a0-435a9338ced1.webp", "path": null, "size": 13.88, "width": 500, "height": 420 }, "medium": { "ext": ".webp", "url": "https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/medium_36888_346a77f7_7e94_4e61_a1a0_435a9338ced1_3d9790c0f0.webp", "hash": "medium_36888_346a77f7_7e94_4e61_a1a0_435a9338ced1_3d9790c0f0", "mime": "image/webp", "name": "medium_36888_346a77f7-7e94-4e61-a1a0-435a9338ced1.webp", "path": null, "size": 26.2, "width": 750, "height": 629 }, "thumbnail": { "ext": ".webp", "url": "https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/thumbnail_36888_346a77f7_7e94_4e61_a1a0_435a9338ced1_3d9790c0f0.webp", "hash": "thumbnail_36888_346a77f7_7e94_4e61_a1a0_435a9338ced1_3d9790c0f0", "mime": "image/webp", "name": "thumbnail_36888_346a77f7-7e94-4e61-a1a0-435a9338ced1.webp", "path": null, "size": 3.03, "width": 186, "height": 156 } }, "hash": "36888_346a77f7_7e94_4e61_a1a0_435a9338ced1_3d9790c0f0", "ext": ".webp", "mime": "image/webp", "size": 53.12, "url": "https://s3.ap-southeast-1.amazonaws.com/virtualprotocolcdn/36888_346a77f7_7e94_4e61_a1a0_435a9338ced1_3d9790c0f0.webp", "previewUrl": null, "provider": "aws-s3", "provider_metadata": null, "createdAt": "2025-08-22T16:17:47.344Z", "updatedAt": "2025-08-22T16:17:47.344Z" }, "genesis": null, "stats": { "contributionsCount": 0, "contributorsCount": 0, "contributionVersions": [], "totalStakeAmount": "0.0", "stakerCount": 0, "validatorCount": 0 }, "characterDescription": "", "projectMembers": [ { "id": 31711, "isAccepted": true, "title": "Owner", "createdAt": "2025-08-22T16:16:02.107Z", "updatedAt": "2025-08-22T16:16:02.107Z", "walletAddress": "0x02908957173ae116d59E84d3fAdd7953183D513A", "virtual": { "id": 36888, "creator": { "id": 496449 } }, "user": { "id": 496449, "socials": null, "bio": null, "avatar": null, "walletAddress": "0x02908957173ae116d59E84d3fAdd7953183D513A" } } ], "tokenomics": [], "tokenomicsStatus": { "hasUnlocked": true, "daysFromFirstUnlock": 0 }, "multichainAgents": [] } </full_details>

Investment info last updated: Aug 22, 2025 16:39